Add BrightSurf on Google Email

Science News for May 20, 2004


Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment

Researchers found that a weekly cycle of once-daily anti-HIV drugs can effectively treat HIV infection while reducing medication costs. The study involved eight patients who received a treatment regimen of 7 days on, followed by 7 days off, and maintained undetectable levels of HIV in their bloodstream for up to 84 weeks.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalThe Journal of Infectious Diseases·DateMay 20, 2004

OTC statins: A bad decision for public health

The UK government has rejected proposals to sell simvastatin over-the-counter for the primary prevention of heart disease due to financial reasons. This decision may increase inequalities as many people cannot afford the medication, which is currently prescribed to around 1.8 million people in the UK.

SourceThe Lancet_DELETED·JournalThe Lancet·DateMay 20, 2004

The worldwide prevalence of glaucoma is increasing

Glaucoma is a group of disorders that progressively damage the optic nerve, affecting 66 million people worldwide. Early detection through comprehensive eye assessments, including optic disc examination, is crucial for limiting vision loss and advancing treatment. Current therapies can limit vision loss if identified in early stages.

SourceThe Lancet_DELETED·JournalThe Lancet·DateMay 20, 2004

Poor kids' health insurance situation changes often, affecting their medical care, study finds

A study by Michigan Medicine found that over 5.7 million low-income children experience a transition in their health insurance each year, leading to postponed doctor visits and prescriptions. The study highlights the need for consistent coverage and minimized barriers to ensure these children receive needed care.

SourceMichigan Medicine - University of Michigan·JournalAmbulatory Pediatrics·DateMay 20, 2004

Zinc can help in the treatment of pneumonia

A zinc supplement reduced treatment time for severe pneumonia in children by an average of one day, with a corresponding decrease in hospital stay duration. The treatment was also found to be safe and well-tolerated, with significant implications for reducing antimicrobial resistance.

SourceThe Lancet_DELETED·JournalThe Lancet·DateMay 20, 2004